Spero Therapeutics Inc. [NASDAQ: SPRO] traded at a high on 09/29/20, posting a 6.99 gain after which it closed the day’ session at $9.95.
The results of the trading session contributed to over 1342538 shares changing hands. Over the past one week, the price volatility of Spero Therapeutics Inc. stands at 5.94% while the volatility over the past one month is 9.62%.
The market cap for SPRO stock reached $252.93 million, with 20.63 million shares outstanding and 14.81 million shares in the current float. Compared to the average trading volume of 289.89K shares, SPRO reached a trading volume of 1342538 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Spero Therapeutics Inc. [SPRO]?
Evercore ISI have made an estimate for Spero Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 29, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $28 to $35. The new note on the price target was released on November 05, 2019, representing the official price target for Spero Therapeutics Inc. stock.
The Average True Range (ATR) for Spero Therapeutics Inc. is set at 0.89, with the Price to Sales ratio for SPRO stock in the period of the last 12 months amounting to 21.62. The Price to Book ratio for the last quarter was 2.79, with the Price to Cash per share for the same quarter was set at 2.80.
How has SPRO stock performed recently?
Spero Therapeutics Inc. [SPRO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.16. With this latest performance, SPRO shares dropped by -5.33% in over the last four-week period, additionally plugging by 23.14% over the last 6 months – not to mention a drop of -6.13% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SPRO stock in for the last two-week period is set at 46.93, with the RSI for the last a single of trading hit 48.40, and the three-weeks RSI is set at 45.00 for Spero Therapeutics Inc. [SPRO]. The present Moving Average for the last 50 days of trading for this stock 11.44, while it was recorded at 9.52 for the last single week of trading, and 10.64 for the last 200 days.
Spero Therapeutics Inc. [SPRO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Spero Therapeutics Inc. [SPRO] shares currently have an operating margin of -348.36. Spero Therapeutics Inc.’s Net Margin is presently recorded at -335.73.
Return on Total Capital for SPRO is now -64.51, given the latest momentum, and Return on Invested Capital for the company is -62.59. Return on Equity for this stock declined to -64.11, with Return on Assets sitting at -51.83. When it comes to the capital structure of this company, Spero Therapeutics Inc. [SPRO] has a Total Debt to Total Equity ratio set at 7.44. Additionally, SPRO Total Debt to Total Capital is recorded at 6.92, with Total Debt to Total Assets ending up at 5.23. Long-Term Debt to Equity for the company is recorded at 6.19, with the Long-Term Debt to Total Capital now at 5.76.
Reflecting on the efficiency of the workforce at the company, Spero Therapeutics Inc. [SPRO] managed to generate an average of -$1,068,860 per employee. Receivables Turnover for the company is 3.14 with a Total Asset Turnover recorded at a value of 0.15.Spero Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.50 and a Current Ratio set at 4.50.
Earnings analysis for Spero Therapeutics Inc. [SPRO]
With the latest financial reports released by the company, Spero Therapeutics Inc. posted -0.95/share EPS, while the average EPS was predicted by analysts to be reported at -0.85/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SPRO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Spero Therapeutics Inc. go to 36.90%.
Insider trade positions for Spero Therapeutics Inc. [SPRO]
There are presently around $111 million, or 45.80% of SPRO stock, in the hands of institutional investors. The top three institutional holders of SPRO stocks are: AQUILO CAPITAL MANAGEMENT, LLC with ownership of 1,943,081, which is approximately 6.872% of the company’s market cap and around 0.30% of the total institutional ownership; ATLAS VENTURE ASSOCIATES IX, LLC, holding 1,376,968 shares of the stock with an approximate value of $13.7 million in SPRO stocks shares; and BLACKROCK INC., currently with $9.46 million in SPRO stock with ownership of nearly 7.833% of the company’s market capitalization.
Positions in Spero Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 62 institutional holders increased their position in Spero Therapeutics Inc. [NASDAQ:SPRO] by around 1,234,488 shares. Additionally, 21 investors decreased positions by around 1,004,538 shares, while 4 investors held positions by with 8,954,275 shares. The mentioned changes placed institutional holdings at 11,193,301 shares, according to the latest SEC report filing. SPRO stock had 28 new institutional investments in for a total of 376,549 shares, while 8 institutional investors sold positions of 647,029 shares during the same period.